title: A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles.
abstract: Our aim was to determine the quantitative effects of a single-dose of Nattokinase (NK) administration on coagulation/fibrinolysis parameters comprehensively in healthy male subjects. A double-blind, placebo-controlled cross-over NK intervention study was carried out in 12 healthy young males. Following the baseline blood draw, each subject was randomized to receive either a single-dose of 2,000 FU NK (NSK-SD, Japan Bio Science Laboratory Co., Ltd) or placebo with subsequent cross-over of the groups. Subjects donated blood samples at 2, 4, 6 and 8 hours following administration for analysis of coagulation/fibrinolysis parameters. As a result, D-dimer concentrations at 6, and 8 hours, and blood fibrin/fibrinogen degradation products at 4 hours after NK administration elevated significantly (p < 0.05, respectively). Factor VIII activity declined at 4 and 6 hours (p < 0.05, respectively), blood antithrombin concentration was higher at 2 and 4 hours (p < 0.05, respectively), and the activated partial thromboplastin time prolonged significantly at 2 and 4 hours following NK administration (p < 0.05 and p < 0.01, respectively). All the changes, however, were within the normal range. In conclusion, thus, a single-dose of NK administration appears enhancing fibrinolysis and anti-coagulation via several different pathways simultaneously.
authors.affiliation: Department of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kurosawa
authors.affiliation: Department of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Nirengi
authors.affiliation: Department of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Homma
authors.affiliation: Department of Economics, Tokuyama University, Shunan, Yamaguchi, Japan.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Esaki
authors.affiliation: Department of Clinical Chemistry, Kobe Pharmaceutical University, Kobe, Hyogo, Japan.
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Ohta
authors.affiliation: Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Clark
authors.affiliation: Department of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga, Japan.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Hamaoka
mesh_terms: D000991:Antithrombins / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005169:Factor VIII / Q000378:metabolism; D005337:Fibrin / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D013381:Subtilisins / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D000991:Antithrombins; D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; C036309:fibrin fragment D; D005169:Factor VIII; D005337:Fibrin; D005340:Fibrinogen; D013381:Subtilisins; C053771:nattokinase